Cargando…
Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
Although sorafenib is expected to have a chemopreventive effect on hepatocellular carcinoma (HCC) recurrence, there are limitations to its use because of adverse effects, including effects on liver function. We have reported that the iron chelator, deferoxamine can prevent liver fibrosis and preneop...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
the Society for Free Radical Research Japan
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865599/ https://www.ncbi.nlm.nih.gov/pubmed/27257345 http://dx.doi.org/10.3164/jcbn.15-127 |